Nemiralisib

CAS : 1254036-71-9

Ref. 3D-EAC03671

Informations sur le produit

• Nom: Nemiralisib

Description

Nemiralisib is a small molecule that inhibits the PD-L1 protein. It can be used to treat cancer and autoimmune diseases. Nemiralisib binds to the PD-L1 protein and prevents it from binding to its ligands, CD80 or CD86. This prevents the immune system from being suppressed by the PD-L1 protein and may enable an anti-PD-L1 therapy to induce tumor regression in patients with cancer. Nemiralisib has been shown to inhibit P-glycoprotein (Pgp) activity in vitro, which may result in drug interactions with other drugs that are substrates of this transporter. Nemiralisib has a terminal half life of approximately 6 hours, meaning that most of it will be eliminated from the body within 24 hours after administration. The chemical name for nemiralisib is 1-[3-(4-chlorophenyl)phenyl]-3-[2-(methylsulfonyl)phenyl]urea. The

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 440.54 g/mol
• Formule: C₂₆H₂₈N₆O
• Degré de pureté: Min. 95%